Item Details
19 Nov 2026

VitriVax raises $87 million to develop next generation vaccines

US biotechnology company VitriVax announced an oversubscribed $87 million Series C funding round on 18 November. The investment will support the development of its Lyme disease vaccine and expansion of its wider vaccine pipeline. Investors include F Prime, NEA, RA Capital Management, Sanofi Ventures and Eli Lilly. HPC could connect biotechnology startups with pharmaceutical investors, research partners and specialist manufacturing companies.


If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.

VitriVax raises $87 million to develop next generation vaccines

Get in Touch

We’ll get back to you shortly.